Thompson #AACR19 FinXX trial - 120 TNBC, two arms T + CEF (5-fluoruacil) / Tx + TEX (capecitabine). Profile immune… https://t.co/bfB6BsLCRc

10:25am April 2nd 2019 via Twitter Web Client